群体规模分析揭示遗传性C1抑制剂缺乏是一种多表型血栓性疾病
研究在635 823名参与者中分析遗传定义的C1抑制剂(C1INH/SERPING1)缺乏与血栓风险的关系。SERPING1功能有害编码变异罕见(约1:10 000),携带者血浆C1INH水平显著低于非携带者。校正性别和 ancestry 后,SERPING1单倍剂量不足与静脉血栓栓塞、非心源性栓塞性缺血性卒中及外周动脉疾病风险显著增加相关,心肌梗死呈关联趋势。
要点
- SERPING1功能有害编码变异罕见(约1:10 000),提示强遗传约束。
- 携带者血浆C1INH水平显著低于非携带者(Olink P=.005;ELISA P<.001)。
- 校正性别和 ancestry 后,SERPING1单倍剂量不足与静脉血栓栓塞(HR 4.64)、非心源性栓塞性缺血性卒中(HR 3.29)及外周动脉疾病(HR 3.10)风险显著增加相关。
核心结论
- 遗传性C1INH缺乏在群体尺度上表现为多表型血栓性疾病,与静脉血栓栓塞、非心源性栓塞性缺血性卒中和外周动脉疾病风险增加相关,心肌梗死呈关联趋势。
研究设计与样本
- 在635 823名参与者中开展的群体规模遗传关联分析,研究遗传定义的C1INH缺乏。
主要发现
- SERPING1功能有害种系编码变异罕见(约1:10 000),提示强遗传约束。
- SERPING1变异携带者血浆C1INH水平显著低于非携带者(Olink蛋白质组学 P=.005),并在独立队列中经酶联免疫吸附试验确认(P<.001)。
- 校正性别和 ancestry 后,SERPING1单倍剂量不足与静脉血栓栓塞风险显著增加相关(HR 4.64;95%CI 2.08-10.34;P=.0002)。
- 校正性别和 ancestry 后,SERPING1单倍剂量不足与非心源性栓塞性缺血性卒中风险显著增加相关(HR 3.29;95%CI 1.06-10.19;P=.039)。
- 校正性别和 ancestry 后,SERPING1单倍剂量不足与外周动脉疾病风险显著增加相关(HR 3.10;95%CI 1.29-7.45;P=.011),心肌梗死呈关联趋势(HR 2.77;95%CI 0.89-8.61;P=.077)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deficiency in C1 inhibitor (C1INH/SERPING1) is canonically associated with hereditary angioedema (HAE-C1INH) but not thrombosis. To determine the thrombosis risk conferred by the loss of C1INH in the general population, we studied genetically-defined C1INH deficiency across 635 823 participants. Functionally deleterious germ line coding variation in the SERPING1 gene was rare (∼1:10 000), indicating strong genetic constraint. SERPING1 variant carriers had significantly lower plasma C1INH levels than noncarriers, as determined by Olink proteomics (P = .005) and confirmed by enzyme-linked immunosorbent assay in an independent cohort (P< .001). After adjustment for sex and ancestry, SERPING1 haploinsufficiency was associated with a significantly increased risk of venous thromboembolism (hazard ratio [HR], 4.64; 95% confidence interval [CI], 2.08-10.34; P = .0002), noncardioembolic ischemic stroke (HR, 3.29; 95% CI, 1.06-10.19; P = .039), and peripheral artery disease (HR, 3.10; 95% CI, 1.29-7.45; P = .011), with a trend toward association with myocardial infarction (HR, 2.77; 95% CI, 0.89-8.61; P = .077). Effect size estimates for all 4 thrombosis phenotypes increased when analysis was restricted to only the most functionally deleterious variants. These findings highlight the potential of population-scale data sets to address fundamental questions related to thrombosis risk.
引用
- Rodriguez Espada A, Haj AK, Jurgens SJ, et al. Population-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder. Blood Adv. 2026. PMID: 41026970. doi:10.1182/bloodadvances.2025017220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。